Patent ductus arteriosus and spontaneous intestinal perforation in a cohort of preterm infants

J Perinatol. 2022 Dec;42(12):1649-1653. doi: 10.1038/s41372-022-01403-8. Epub 2022 May 19.

Abstract

Objective: To assess whether either duration and magnitude of ductal shunt or medical treatment for patent ductus arteriosus (PDA) are related to spontaneous intestinal perforation (SIP).

Study design: Clinical charts of infants <29 weeks' gestation born from 2006 to 2018 were reviewed. Echocardiographic examinations were evaluated according to McNamara and Sehgal's staging system.

Results: A higher percentage of patients with SIP had a hemodynamically significant PDA (HSPDA) and was treated with either NSAIDs or paracetamol (79% vs 53% and 81% vs 54%, respectively). Among non-treated patients, we found a 1.32 increase in the odds of SIP per day of persistence of HSPDA. In the cohort of patients treated despite the absence of HSPDA, we found a 2.35 increase in the odds of SIP per dose of drug administered.

Conclusion: Both treating a non-HSPDA and leaving a HSPDA to its natural history seem to be associated with SIP.

MeSH terms

  • Ductus Arteriosus, Patent* / complications
  • Ductus Arteriosus, Patent* / diagnostic imaging
  • Ductus Arteriosus, Patent* / drug therapy
  • Echocardiography
  • Gestational Age
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Intestinal Perforation* / diagnostic imaging